Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/99640
Title: | Major Challenges in clinical management of TB/HIV coinfected patients in Eastern Europe compared with Western Europe and Latin America |
Author: | Efsen, Anne Marie W. Schultze, Anna Post, Frank A. Panteleev, Alexander Furrer, Hansjakob Miller, Robert F. Losso, Marcelo H. Toibaro, Javier Skrahin, Aliaksandr Miró Meda, José M. Caylà i Buqueras, Joan A. Girardi, Enrico Bruyand, Mathias Obel, Niels Podlekareva, Daria N. Lundgren, Jens D. Mocroft, Amanda Kirk, Ole Alcaide Fernández de Vega, Fernando TB:HIV study group in EuroCoord |
Keywords: | Tuberculosi VIH (Virus) Infeccions per VIH Resistència als medicaments Terapèutica Europa de l'Est Europa occidental Amèrica Llatina Tuberculosis HIV (Viruses) HIV infections Drug resistance Therapeutics Eastern Europe Western Europe Latin America |
Issue Date: | 30-Dec-2015 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | Objectives: rates of TB/HIV coinfection and multi-drug resistant (MDR)-TB are increasing in Eastern Europe (EE). We aimed to study clinical characteristics, factors associated with MDR-TB and predicted activity of empiric anti-TB treatment at time of TB diagnosis among TB/HIV coinfected patients in EE, Western Europe (WE) and Latin America (LA). Design and methods: between January 1, 2011, and December 31, 2013, 1413 TB/HIV patients (62 clinics in 19 countries in EE, WE, Southern Europe (SE), and LA) were enrolled. Results: significant differences were observed between EE (N = 844), WE (N = 152), SE (N = 164), and LA (N = 253) in the proportion of patients with a definite TB diagnosis (47%, 71%, 72% and 40%, p<0.0001), MDR-TB (40%, 5%, 3% and 15%, p<0.0001), and use of combination antiretroviral therapy (cART) (17%, 40%, 44% and 35%, p<0.0001). Injecting drug use (adjusted OR (aOR) = 2.03 (95% CI 1.00-4.09), prior anti-TB treatment (3.42 (1.88-6.22)), and living in EE (7.19 (3.28-15.78)) were associated with MDR-TB. Among 585 patients with drug susceptibility test (DST) results, the empiric (i.e. without knowledge of the DST results) anti-TB treatment included ≥3 active drugs in 66% of participants in EE compared with 90-96% in other regions (p<0.0001). Conclusions: in EE, TB/HIV patients were less likely to receive a definite TB diagnosis, more likely to house MDR-TB and commonly received empiric anti-TB treatment with reduced activity. Improved management of TB/HIV patients in EE requires better access to TB diagnostics including DSTs, empiric anti-TB therapy directed at both susceptible and MDR-TB, and more widespread use of cART. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0145380 |
It is part of: | PLoS One, 2015, vol. 10, num. 12, p. e0145380 |
URI: | http://hdl.handle.net/2445/99640 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0145380 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Medicina) Publicacions de projectes de recerca finançats per la UE |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
662116.pdf | 871.94 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License